MedTrace Logo

Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies

NCT00430547 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2007-02-02

No results posted yet for this study

Summary

The purpose of this study is to determine whether radioactive iodine, as compared to anti-thyroid medications, is a risk factor for the development or progression of thyroid-associated ophthalmopathy in patients with hyperthyroidism due to Graves' disease. The other aim of this study is to determine the incidence of the various ophthalmopathy subtypes and the utility of orbital antibodies in the diagnosis, classification and monitoring of patients with thyroid-associated ophthalmopathy.

Conditions

  • Graves' Ophthalmopathy

Interventions

DRUG

Carbimazole, radio-active iodine (I131)

Sponsors & Collaborators

  • University of Melbourne

    collaborator OTHER

  • National Health and Medical Research Council, Australia

    collaborator OTHER

  • Barwon Health

    lead OTHER_GOV

Principal Investigators

  • Jack R Wall, BMBS, FRACP, PhD · University of Sydney

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-08-31
Completion
2006-01-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00430547 on ClinicalTrials.gov